On December 20, Glonghui reported that Zhejiang Ausun Pharmaceutical (603229.SH) announced that its partner STADA Arzneimittel AG's wholly-owned subsidiary Eurogenerics received the marketing authorization for imatinib mesylate tablets issued by the Belgian Federal Agency for Medicines and Health Products.

Imatinib mesylate tablets are the first global molecular targeted antitumor drug used for the treatment of patients in the chronic phase after acute phase, accelerated phase, or failure of α-interferon therapy in chronic myeloid leukemia (CML), and for patients with malignant gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have metastasized. Its active ingredient, imatinib, is a tyrosine kinase inhibitor that effectively suppresses the Philadelphia chromosome gene, inhibiting the phosphorylation reaction, leading to the loss of function of the chromosome and subsequently suppressing the abnormal proliferation of white blood cells; it can also bind to the active site of the tyrosine kinase and prevent its activity.